contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment CompanyTagList on Company {
  pageUrl
  name
  viewerIsFollowing
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    ...CompanyTagList
    id
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      defaultInstrument {
        isin
        id
      }
      id
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    id
    name
    viewerIsFollowing
    defaultInstrument {
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


__typename

title

isPremium

lang

htmlBody

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Analyst

Anton Damstén

SciBase Holding is a global medical technology group specialized in diagnostics and prevention in dermatology. The company develops, produces and commercializes Nevisense, a patient-centered platform that combines AI (artificial intelligence) with EIS technology to enable early detection and intervention of skin cancer and other skin diseases. Nevisense is based on over 20 years of research at Karolinska Institutet, the headquarters are in Stockholm.

Marksnadsvärden av bolagen är mycket låg om någon vill köpa hela bolaget.  Men är detta mögligt att köpä ut av börsen? Kenner någon här största aktieägarna eller vet hur dom brukar agera?

Mikael Maijala intervjuade Antti Luiro om SciBase i dag SciBase Q3’24: Waiting for the clear waters

SciBase har ingått ett partnerskap med den italienska distributören Kilabs för att underlätta inträdet på den italienska marknaden genom att utnyttja Kilabs lokala distributionsexpertis. SciBase anpassar sin Nevisense-teknologi för att uppfylla italienska regler, och lansering planeras till första halvåret 2025. Detta partnerskap stödjer SciBases mål om kassaflödesneutralitet genom att minska initiala investeringar och fokusera på hållbar tillväxt.                    Inderes              SciBase prepares to enter Italy through a sales and distribution partnership...    SciBase's new partner, Kilabs, is an Italy-based distributor of medical technologies focused on several specialties, including dermatology. The announced partnership should help provide SciBase with a distribution and sales channel in Italy.

SciBase har ingått ett samarbete med Seraly Dermatology i Pittsburgh. Kunden kommer att integrera flera Nevisense-system i processen för att upptäcka hudcancer. Seraly Dermatology verkar vara en liten aktör, men varje ny kund stärker Nevisense-produktens goda marknadsposition.                    Inderes              SciBase lands another customer in the US - Inderes    The announced partnership is with Seraly Dermatology in Pittsburgh, Pennsylvania. Each customer win is a sign that the market response to Nevisense remains good and that the product continues to be well positioned.

Kortkommentarer på SciBase angående aktuella nyheter och förändringar + kommande stegen framöver för bolaget.

Här även en aktuell video, som sammanfattar nuläget riktigt bra!  Krångligt case, enligt mig. Potential finns, men det lär nog dröja innan man når positiva kassaströmmar.                   Inderes              SciBase Q2’24: Forward - but positive cash flow still in the distance - Inderes    Time: 2024-08-23 10:15 Important partnerships established in the USA, first order received from Austria. Cash burn is still high. Analyst Antti Luiro summarizes.

Ny analys ute på SciBase:  Omsättningstillväxten nådde inte upp till förväntningarna under Q2, men kassaflödet var fortsatt stabilt. Stegen mot snabbare tillväxt i USA fortsätter, och en lokal konkurrents konkurs har gett SciBase utrymme att ta marknadsandelar.                   Inderes              SciBase Q2'24: Still waiting for more signals of accelerating growth - Inderes    SciBase’s revenue growth fell short of expectations in Q2, but cash burn remained stable. Steps towards faster growth in the US continue.

Scibase Holding

On the back of its innovative skin cancer detection device, Nevisense, SciBase has experienced significant revenue growth in recent years. With the company currently expanding into the US market...

<p>On the back of its innovative skin cancer detection device, Nevisense, SciBase has experienced significant revenue growth in recent years. With the company currently expanding into the US market, we find the potential for even higher revenue growth credible. However, the company has yet to turn a profit and has been, and likely continues to be, reliant on equity offerings to fund its operations. In addition, visibility into the complex US healthcare industry is poor, which makes predicting the timing of cash flow positivity an uncertain prospect. Therefore, while we have a strong positive outlook for the Nevisense device and anticipate high revenue growth, the above factors lead us to consider the share appropriately priced in the near term</p> 